Hyperparathyroidism and Calcium Disorders

Hyperparathyroidism and related calcium disorders represent a significant category of endocrine disease, with primary hyperparathyroidism affecting an estimated 1 in 500 to 1 in 1,000 adults in the United States (National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK). These conditions involve abnormal regulation of calcium, phosphorus, and parathyroid hormone (PTH), producing consequences that range from asymptomatic laboratory findings to serious skeletal and renal complications. Understanding the classification, mechanism, and clinical boundaries of these disorders is foundational to the broader landscape of endocrine care covered across Endocrinology Authority. Regulatory and diagnostic standards relevant to these conditions are governed by professional bodies including the American Association of Clinical Endocrinology (AACE) and addressed within the regulatory context for endocrinology.

Definition and Scope

Hyperparathyroidism is defined by excessive secretion of parathyroid hormone from one or more of the four parathyroid glands, leading to disordered calcium homeostasis. The condition is classified into three principal types, each with distinct etiologies and clinical implications:

  1. Primary hyperparathyroidism (PHPT) — autonomous overproduction of PTH, most commonly caused by a single benign adenoma (approximately 80–85% of cases, per NIDDK)
  2. Secondary hyperparathyroidism (SHPT) — compensatory PTH elevation in response to hypocalcemia or vitamin D deficiency, frequently associated with chronic kidney disease (CKD) stages 3–5
  3. Tertiary hyperparathyroidism — autonomous PTH secretion that develops after prolonged secondary stimulation, particularly in patients on long-term renal dialysis or following kidney transplantation

Hypercalcemia — serum calcium above 10.5 mg/dL by standard laboratory reference ranges — is the hallmark biochemical finding in PHPT and tertiary disease. Hypocalcemia, by contrast, characterizes secondary hyperparathyroidism until the compensatory mechanism fails or is overwhelmed.

The inverse condition, hypoparathyroidism, involves insufficient PTH production, most commonly after inadvertent parathyroid removal during thyroid surgery. The American Thyroid Association (ATA) recognizes post-surgical hypoparathyroidism as the leading cause of chronic hypoparathyroidism in the United States.

How It Works

PTH is produced by chief cells in the parathyroid glands and acts through three coordinated mechanisms to raise serum calcium:

  1. Renal tubular reabsorption — PTH increases calcium reabsorption in the distal convoluted tubule while simultaneously promoting phosphate excretion
  2. Bone resorption — PTH activates osteoclasts via RANK-L signaling pathways, releasing calcium and phosphorus from bone matrix into circulation
  3. Intestinal absorption — PTH stimulates renal 1-alpha-hydroxylase, converting 25-hydroxyvitamin D to its active form (1,25-dihydroxyvitamin D / calcitriol), which enhances intestinal calcium absorption

In PHPT, a parathyroid adenoma secretes PTH autonomously, bypassing the normal negative feedback from elevated serum calcium. The result is persistent hypercalcemia, elevated or inappropriately normal PTH levels, low-normal serum phosphorus, and increased urinary calcium excretion (hypercalciuria). Over time, sustained PTH excess drives cortical bone loss — particularly at the distal one-third of the radius — and increases the risk of nephrolithiasis. The DEXA scan and bone density assessment is one standard tool used to quantify skeletal impact.

In secondary hyperparathyroidism, the driver is chronically low calcium or low calcitriol. The parathyroids respond appropriately but excessively, and prolonged stimulation can cause glandular hyperplasia across all four glands. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provide the primary international framework for managing mineral and bone disorder in CKD, including targets for PTH, calcium, phosphorus, and vitamin D metabolites.

Common Scenarios

Asymptomatic PHPT is the presentation encountered in the majority of cases diagnosed in the United States since the widespread adoption of automated serum chemistry panels in the 1970s. A patient receives routine bloodwork, calcium is flagged at 10.8–11.5 mg/dL, and subsequent intact PTH is elevated or high-normal. Symptoms, if present, may include fatigue, mild cognitive changes, constipation, or polyuria.

Symptomatic PHPT follows the traditional mnemonic "bones, stones, groans, and psychic moans": osteitis fibrosa cystica (now rare in developed countries), nephrolithiasis (occurring in approximately 15–20% of PHPT patients per NIDDK), gastrointestinal complaints, and neuropsychiatric symptoms.

Hypercalcemic crisis represents the acute extreme, with serum calcium exceeding 14 mg/dL, requiring hospitalization, aggressive IV hydration, and potentially calcitonin or bisphosphonate therapy. This is a medical emergency.

Secondary SHPT in CKD patients manifests through elevated PTH (often exceeding 300 pg/mL in advanced CKD stage 5), hyperphosphatemia, low or low-normal calcium, and vascular calcification risk. Management intersects with medications for osteoporosis and renal disease protocols.

Post-surgical hypoparathyroidism presents with hypocalcemia, perioral tingling, muscle cramps, and in severe cases, tetany or laryngospasm within hours to days following thyroid or parathyroid surgery.

Decision Boundaries

Endocrinology guidelines establish explicit thresholds for when surgical intervention versus monitoring is appropriate in PHPT. The Fourth International Workshop on Asymptomatic Primary Hyperparathyroidism (published in the Journal of Clinical Endocrinology & Metabolism, 2014) established operative indications that include:

  1. Serum calcium more than 1.0 mg/dL above the upper limit of normal
  2. Creatinine clearance below 60 mL/min
  3. T-score at or below −2.5 at the lumbar spine, total hip, femoral neck, or distal one-third radius
  4. Age under 50 years
  5. 24-hour urinary calcium exceeding 400 mg/day combined with elevated stone risk on biochemical analysis

Patients who do not meet surgical criteria are candidates for monitoring: annual serum calcium and creatinine, bone density every 1–2 years via DEXA, and renal imaging if nephrolithiasis risk factors are present.

Differentiating PHPT from familial hypocalciuric hypercalcemia (FHH) is a critical decision boundary. FHH is a benign, autosomal dominant condition caused by inactivating mutations in the calcium-sensing receptor (CaSR) gene. The calcium-to-creatinine clearance ratio (CCCR) below 0.01 strongly suggests FHH, where parathyroid surgery is contraindicated. Genetic testing confirming CaSR, AP2S1, or GNA11 mutations resolves ambiguous cases.

Cinacalcet, a calcimimetic agent approved by the U.S. Food and Drug Administration (FDA) for secondary hyperparathyroidism in dialysis patients and for inoperable or metastatic parathyroid carcinoma, works by increasing CaSR sensitivity to extracellular calcium, thereby suppressing PTH secretion without directly lowering mineral levels through skeletal action.

The boundary between primary and secondary disease also matters for vitamin D supplementation: in PHPT, aggressive vitamin D repletion can worsen hypercalcemia, requiring careful dose titration, typically with serum 25-hydroxyvitamin D maintained above 20 ng/mL while monitoring calcium response.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)